This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The effectiveness and resource use data were collected between January 1st 1995 and 31st December 2000. All costs were reported for the price year 2001.
Source of effectiveness data
The current study was a modelling study (survival analysis). The effectiveness data were derived from a parent observational cohort study and from administrative records from the database of the Lovelace Patient HMO.
Link between effectiveness and cost data
Although not explicitly stated, the costing appears to have been carried out retrospectively on the same sample of patients as that used in the effectiveness study.
Study sample
The sample size was not determined in the planning phase of the study. In addition, power calculations were not performed retrospectively. Patients at the Lovelace HMO who met the inclusion criteria were included in the study sample. No patients were reported to have refused to participate. Overall, 1,154 patients with a mean age of 66 years and roughly equal proportions of men and women were recruited into the study. Of those, 274 patients comprised the "comparison" treatment group, 538 the ICS alone group, 130 the LABA alone group, and 212 the ICS+LABA group.
Study design
The analysis was based on an observational single-centre cohort study. Data were collected from records from 1st January 1995 until 31st December 2000. For each patient, data were collected from the first day after a 90-day drug treatment course until 31 December 2000, unless the patient died.
Analysis of effectiveness
It was not stated whether the analysis was conducted on an intention to treat basis. The authors reported that differences between treatment groups were observed in relation to demographic and disease severity characteristics. The primary health outcomes were survival at 36 months and survival over the patients-lifetime. A Cox proportional hazards model was used for the former and a parametric proportional hazards regression model, based on a Gompertz distribution, for the latter. The authors constructed a random-effects model with generalised least-squares estimator to adjust for prognostic factors. Life expectancy was discounted at a rate of 5%.
Effectiveness results
In the within-study analysis (survival at 36 months), the discounted life expectancy was 2.41 years (95% confidence interval, CI: 2.30 to 2.55) in the "comparison" treatment group, 2.60 years (95% CI: 2.56 to 2.68) in the ICS alone group, 2.63 years (95% CI: 2.53 to 2.74) in the LABA alone group, and 2.70 years (95% CI: 2.64 to 2.78) in the ICS+LABA group.
In the lifetime analysis, discounted life expectancy was estimated to be 3.88 years (95% CI: 3.25 to 5.02) in the "comparison" treatment group, 5.06 years (95% CI: 4.34 to 6.6) in the ICS alone group, 5.27 years (95% CI: 4.19 to 7.21) in the LABA alone group, and 6.14 years (95% CI: 4.89 to 8.63) in the ICS+LABA group.
Clinical conclusions
The analysis demonstrated that, compared with other drug treatments, ICS, LABA or their combination result in greater life expectancy for patients with COPD. $28,030 (95% CI: 23,400 to 33,750) in the comparison group, $35,170 (95% CI: 29,970 to 40,620) in the ICS alone group, $27,380 (95% CI: 21,780 to 32,510) in the LABA group, and $33,780 (95% CI: 28,700 to 39,440) in the ICS+LABA group.
When a lifetime analysis was conducted, the total discounted cumulative costs were $48,950 (95% CI: 31,800 to 72,500) in the comparison group, $71,860 (95% CI: 50,900 to 103,180) in the ICS group, $57,500 (95% CI: 32,380 to 91,720) in the LABA group, and $79,560 (95% CI: 50,020 to 122,070) in the ICS+LABA group.
Synthesis of costs and benefits
An incremental cost-effectiveness analysis was performed. The incremental cost-effectiveness ratio between pairs of treatment options was estimated by dividing the difference in expected costs by the differences in life expectancy.
It was reported that in the within-study analysis (i.e. 36 months), the comparison group and the ICS alone group resulted in higher costs and less effectiveness than LABA alone (these options were dominated). The ICS+LABA treatment option resulted in an incremental cost of $91,430 per additional life-year gained in comparison with LABA alone.
In the lifetime analysis, the ICS alone group resulted in higher costs and less effectiveness than LABA alone (this option was dominated). When the LABA alone treatment option was compared with the comparison option (i.e. no ICS or LABA), it resulted in an incremental cost of $6,110 per additional life-year gained. When the ICS+LABA treatment was compared with LABA alone, it resulted in an incremental cost of $27,570 per additional life-year gained.
The sensitivity analysis demonstrated that higher uncertainty was observed for the results of the within-study analysis, as demonstrated through the wider CIs around the costs and effects and through the broader dispersion of the bootstrap replicates.
The cost-effectiveness acceptability curves verified that the LABA treatment option was the preferred option for WTP values of less than $91,000 per year of life gained. For values of WTP higher than $91,000, ICS+LABA was the most cost-effective treatment option.
On the other hand, the lifetime analysis demonstrated that the "comparison" treatment option (i.e. no ICS or LABA) was the preferred option for a WTP of less than $6,100. LABA alone became the preferred option for a WTP of between $6,100 and $27,500, while for a WTP of greater than $27,500, the ICS+LABA treatment option demonstrated the best value for money.
